Is GRAL a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for GRAIL (GRAL) rests on Galleri volume and revenue growth: Galleri test volume grew roughly 50% year over year in Q1 2026 to more than 56,000 tests, and Galleri revenue rose about 37% to roughly $39.8 million. Revenue (TTM) is ~$156M. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: GRAIL is unprofitable, posting a net loss of roughly $93 million in Q1 2026 and a trailing-twelve-month loss near $395 million, so it depends on its cash balance and eventual funding rather than current earnings. Whether GRAL is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
GRAIL, Inc. develops and sells the Galleri multi-cancer early detection (MCED) test, a blood draw that looks for DNA shed by tumors to screen for dozens of cancer types, including many (pancreatic, ovarian, esophageal, liver) that have no standard screening today. The company was originally incubated inside Illumina and became an independent public company after a court-ordered spin-off in 2024, and it now trades on Nasdaq under GRAL. Galleri is sold largely out-of-pocket and through employer and health-system channels while GRAIL pursues regulatory approval and broad insurance reimbursement. The investment picture is a classic high-growth, high-burn diagnostics profile. Revenue is real and growing quickly (Galleri volumes rose about 50% year over year in Q1 2026), but the company runs large losses as it funds commercial scale-up, clinical trials, and manufacturing. GRAIL submitted a premarket approval (PMA) application to the FDA in January 2026 and has a large cash cushion, so the story hinges on whether Galleri wins regulatory approval, gets added to screening guidelines, and secures Medicare and commercial reimbursement that would move it from a cash-pay niche to a mass-market screening tool.
What's the case for buying GRAL?
1. Galleri volume and revenue growth
Galleri test volume grew roughly 50% year over year in Q1 2026 to more than 56,000 tests, and Galleri revenue rose about 37% to roughly $39.8 million. Management reiterated full-year revenue growth guidance in the low-to-mid 20s percent range. Continued volume compounding is the core driver of the equity story.
2. FDA approval pathway
GRAIL submitted a PMA application for Galleri to the FDA in January 2026, and the agency accepted it for review. An approval would be the first for a true blood-based multi-cancer screening test and would open the door to guideline inclusion and broad payer coverage. The timing and outcome of that review is the single largest swing factor for the stock.
3. Reimbursement and distribution reach
Galleri is still largely cash-pay, so the shift to insurance and Medicare coverage is what could unlock mass adoption. GRAIL announced an Epic electronic-health-record integration that lets physicians order Galleri and view results across a large base of health systems, expanding the ordering funnel ahead of any coverage decisions.
4. Clinical evidence base
Large studies such as the PATHFINDER 2 study (~35,000 participants) and the NHS-Galleri trial (~140,000 participants) are generating the outcomes data that guidelines committees and payers require. Positive readouts strengthen the case for approval and coverage, while disappointing data on real-world detection or false positives would undercut the thesis.
What are the risks to GRAL?
GRAIL is unprofitable, posting a net loss of roughly $93 million in Q1 2026 and a trailing-twelve-month loss near $395 million, so it depends on its cash balance and eventual funding rather than current earnings. The business is concentrated in essentially one product, Galleri, which leaves it exposed to any single negative FDA, clinical, or reimbursement outcome. Competition in multi-cancer detection is intensifying from Exact Sciences (Cancerguard), Guardant Health (Shield), Freenome, and others. Cash burn is heavy (operating cash flow was roughly negative $290 million over the trailing year), and if approval or coverage is delayed, the company may need to raise capital, which could dilute shareholders. The stock is also volatile and trades on a high price-to-sales multiple with no earnings support.
How is GRAL valued? (as of JULY 2026)
Snapshot for GRAL as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$156M
- Q1 2026 revenue (YoY): ~$40.8M (+28%)
- Net loss (TTM): ~-$395M
- Cash & short-term investments: ~$823M
- Market cap: ~$3.0B
- Price / sales (TTM): ~17x
GRAIL trades on revenue growth and its cash runway rather than earnings, since it is deeply unprofitable while it scales Galleri. The roughly $823 million cash position against a trailing operating cash burn near $290 million a year implies a multi-year runway before any need to raise capital. The high price-to-sales multiple reflects investor expectations tied to FDA approval and future reimbursement, not present profitability.
How do you decide if GRAL is a buy?
Rather than asking whether GRAL is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold GRAL indirectly through an index or sector ETF before adding more.
For the full picture, see the GRAL stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about GRAL against your real portfolio and see your actual exposure before deciding.
The bottom line on GRAL
The bottom line: GRAIL's story right now is Galleri volume and revenue growth, with revenue (ttm) at ~$156M. If you believe that narrative continues, the call is about sizing GRAL sensibly and checking overlap with what you own; if you doubt it (the risk: gRAIL is unprofitable, posting a net loss of roughly $93 million in Q1 2026 and a trailing-twelve-month loss near $395 million, so it depends on its cash balance and eventual funding rather than current earnings.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around GRAL with Walnut
Use GRAIL as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is GRAL a good stock to buy right now?
+
The case for GRAIL right now is Galleri volume and revenue growth, with revenue (ttm) at ~$156M. If you believe that thesis holds, GRAL is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is gRAIL is unprofitable, posting a net loss of roughly $93 million in Q1 2026 and a trailing-twelve-month loss near $395 million, so it depends on its cash balance and eventual funding rather than current earnings. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does GRAIL do?
+
GRAIL, Inc.
What are the main risks of GRAL?
+
GRAIL is unprofitable, posting a net loss of roughly $93 million in Q1 2026 and a trailing-twelve-month loss near $395 million, so it depends on its cash balance and eventual funding rather than current earnings. The business is concentrated in essentially one product, Galleri, which leaves it exposed to any single negative FDA, clinical, or reimbursement outcome. Competition in multi-cancer detection is intensifying from Exact Sciences (Cancerguard), Guardant Health (Shield), Freenome, and others. Cash burn is heavy (operating cash flow was roughly negative $290 million over the trailing year), and if approval or coverage is delayed, the company may need to raise capital, which could dilute shareholders. The stock is also volatile and trades on a high price-to-sales multiple with no earnings support.
What does GRAIL (GRAL) do?
+
GRAIL sells the Galleri multi-cancer early detection test, a blood draw that screens for DNA shed by tumors to detect many types of cancer at once, including cancers that currently have no routine screening. It is a commercial-stage diagnostics company, not a therapeutics maker.
Is GRAIL profitable?
+
No. GRAIL generates real and growing revenue from Galleri but runs large losses, with a net loss of roughly $93 million in Q1 2026 and about $395 million over the trailing twelve months as it funds commercial scale-up and clinical trials. Low profitability is normal for a company at this stage.
How much revenue does GRAIL make?
+
Trailing-twelve-month revenue is roughly $156 million as of mid-2026, with Q1 2026 revenue near $40.8 million, up about 28% year over year. Most of that comes from the Galleri test, whose volumes grew around 50% year over year.
What is the Galleri test?
+
Galleri is a blood-based multi-cancer early detection screening test. It looks for tumor DNA signatures to flag the possible presence of cancer and can point to where in the body a signal is coming from. It is designed to complement, not replace, existing single-cancer screenings.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell GRAL; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.